Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Inhibitex, Inc.
Inhibitex Reports Fourth Quarter and Calendar Year 2008 Financial Results and Highlights
March 25th, 2009
Inhibitex, Inc. (NASDAQ: INHX) announced its financial results for the fourth quarter and year ended December 31, 2008. “We are pleased with the progress we have made over the last year, resulting in the achievement of three primary goals,” stated Russell H. Plumb, President and CEO of Inhibitex, Inc. “These goals were to successfully complete our Phase I program for FV-100, identify a lead candidate from our series of HCV nucleoside polymerase inhibitors for further preclinical development, and reduce our overhead costs to extend our cash runway in this challenging business environment. Accordingly, we believe we are well positioned to move our development programs to...
Source: Vaccine Weekly (2009-03-25)
|
